Profile data is unavailable for this security.
About the company
Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions. Tecarfarin has orphan drug and fast track designations from the United States Food and Drug Administration for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). It is also pursuing additional regulatory strategies for unmet needs in anticoagulation therapy for patients with left ventricular assist devices (LVADs) and those with thrombotic antiphospholipid syndrome (APS). Tecarfarin is specifically designed to leverage a different metabolism pathway than the commonly prescribed Vitamin K Antagonist (warfarin).
- Revenue in USD (TTM)0.00
- Net income in USD-6.24m
- Incorporated2022
- Employees4.00
- LocationCadrenal Therapeutics Inc822 A1a North, Suite 300PONTE VEDRA 32082United StatesUSA
- Phone+1 (904) 300-0701
- Fax+1 (302) 655-5049
- Websitehttps://www.cadrenal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geovax Labs Inc | 300.68k | -26.92m | 25.48m | 17.00 | -- | -- | -- | 84.73 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Ocean Biomedical Inc | 0.00 | -98.59m | 25.64m | 9.00 | -- | -- | -- | -- | -3.01 | -3.01 | 0.00 | -2.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2443 | -- | -- | -- | -- | 72.16 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -7.51m | 25.90m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -39.11m | 25.92m | 35.00 | -- | 1.29 | -- | 2,592.26 | -0.6071 | -0.6071 | 0.0002 | 0.3111 | 0.0002 | -- | 0.0685 | 285.71 | -90.71 | -43.60 | -103.87 | -47.82 | -- | -- | -391,132.40 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| RenovoRx Inc | 0.00 | -8.11m | 26.15m | 8.00 | -- | 2.82 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -20.13m | 27.20m | 9.00 | -- | -- | -- | -- | -2.98 | -2.98 | 0.00 | -0.3049 | 0.00 | -- | -- | 0.00 | -307.64 | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -378.19 | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -305.52m | 27.27m | 5.00 | -- | -- | -- | -- | -8.40 | -8.40 | 0.00 | -0.7144 | 0.00 | -- | -- | 0.00 | -6,646.10 | -- | -- | -- | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -6.24m | 27.47m | 4.00 | -- | 4.43 | -- | -- | -5.88 | -5.88 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -138.35 | -- | -173.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.47 | -- | -- | -- |
| Equillium Inc | 42.62m | -8.32m | 27.65m | 45.00 | -- | 1.23 | -- | 0.6486 | -0.2377 | -0.2377 | 1.20 | 0.6333 | 0.8388 | -- | 8.85 | 968,704.60 | -16.37 | -46.81 | -29.58 | -57.36 | -- | -- | -19.52 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| ImmuCell Corp | 23.22m | -4.05m | 27.65m | 74.00 | -- | 1.18 | -- | 1.19 | -0.521 | -0.521 | 2.99 | 2.99 | 0.5409 | 2.32 | 13.47 | 293,961.10 | -9.43 | -5.16 | -10.50 | -5.53 | 26.05 | 40.04 | -17.44 | -12.64 | 0.7668 | -7.43 | 0.3243 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
| Lipocine Inc | 4.80m | -8.49m | 27.70m | 17.00 | -- | 1.31 | -- | 5.77 | -1.60 | -1.60 | 0.9012 | 3.97 | 0.1794 | -- | 109.27 | 282,407.70 | -31.72 | -39.32 | -34.05 | -45.87 | -- | -- | -176.80 | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -109.22m | 28.06m | 65.00 | -- | 0.4902 | -- | -- | -2.85 | -2.85 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -80.62 | -30.73 | -101.80 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Kairos Pharma Ltd | 0.00 | -2.01m | 28.38m | -- | -- | -- | -- | -- | -0.1562 | -0.1562 | 0.00 | -0.2067 | 0.00 | -- | -- | -- | -199.80 | -- | -- | -- | -- | -- | -- | -- | -- | -15.58 | -- | -- | -- | -- | -72.57 | -- | -- | -- |
| IGC Pharma Inc | 1.06m | -13.30m | 28.44m | 67.00 | -- | 3.52 | -- | 26.78 | -0.2104 | -0.2104 | 0.0167 | 0.1042 | 0.0809 | 0.2028 | 8.40 | 15,850.75 | -101.29 | -42.46 | -122.91 | -46.07 | 60.36 | 20.95 | -1,252.64 | -730.00 | 1.16 | -- | 0.0173 | -- | 47.64 | -23.45 | -12.98 | -- | 53.72 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 29.57m | 4.00 | -- | 8.49 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
Data as of Nov 14 2024. Currency figures normalised to Cadrenal Therapeutics Inc's reporting currency: US Dollar USD
2.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avantax Planning Partners, Inc.as of 30 Jun 2024 | 7.55k | 0.71% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.10k | 0.39% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 3.97k | 0.37% |
| Citadel Securities LLCas of 30 Jun 2024 | 3.64k | 0.34% |
| Virtu Americas LLCas of 30 Jun 2024 | 1.65k | 0.16% |
| Two Sigma Securities LLCas of 30 Jun 2024 | 1.06k | 0.10% |
| Biltmore Family Office LLCas of 30 Jun 2024 | 733.00 | 0.07% |
| Tower Research Capital LLCas of 30 Jun 2024 | 644.00 | 0.06% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 5.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
